Nuclear Receptor & In Vitro Toxicology Solutions™

Get all the latest news from INDIGO

  • This field is for validation purposes and should be left unchanged.

  • ABOUT
    • About INDIGO
    • Why INDIGO
    • Key Personnel
      • Board of Directors & Advisors
      • Management
    • Employment
    • INDIGO Press Releases
    • INDIGO in the News
  • ASSAYS
    • By Receptor
    • By Disease State
      • Overview
      • Anemia & Kidney Disease
      • Autoimmune Disease & Inflammation
      • Cancer
      • Cardiovascular Disease
      • Diabetes
      • Endocrinology
      • NAFLD/NASH
      • Obesity
    • Toxicology Solutions
      • In Vitro Toxicology Platform
      • Gene Expression
      • MDR1 / Human P-Glycoprotein
      • Discovery Toxicology
      • Environmental Monitoring
    • INDIGlo Luciferase Detection Reagent
    • Live Cell Multiplex
    • Ortholog Assays
    • Custom Assay Development
  • TECHNOLOGY
    • Nuclear Receptor Overview
    • Assay Kit Platform & Formats
    • Nuclear Receptor Profiling & Panels
    • Environmental Testing Solutions
    • Growth Factor Receptors
    • upcyte® Hepatocytes
    • FAQ
  • RESOURCES
    • Technical Manuals
    • Safety Data Sheets
    • Scientific Whitepapers from INDIGO
    • Scientific Posters
    • New Research Publications
    • Nuclear Receptor Resource
  • CONTACT US
    • Contact INDIGO
    • Request a Quote
    • Request Information
    • Distributors
    • Terms & Conditions
      • Product Policies
      • Limited Use Disclosures
  • BLOG

Nuclear Receptor & In Vitro Toxicology Solutions™

Search site...

± α β γ δ Δ ε ζ κ ω ö ® ™ µ

  • ABOUT
    • About INDIGO
    • Why INDIGO
    • Key Personnel
      • Board of Directors & Advisors
      • Management
    • Employment
    • INDIGO Press Releases
    • INDIGO in the News
  • ASSAYS
    • By Receptor
    • By Disease State
      • Overview
      • Anemia & Kidney Disease
      • Autoimmune Disease & Inflammation
      • Cancer
      • Cardiovascular Disease
      • Diabetes
      • Endocrinology
      • NAFLD/NASH
      • Obesity
    • Toxicology Solutions
      • In Vitro Toxicology Platform
      • Gene Expression
      • MDR1 / Human P-Glycoprotein
      • Discovery Toxicology
      • Environmental Monitoring
    • INDIGlo Luciferase Detection Reagent
    • Live Cell Multiplex
    • Ortholog Assays
    • Custom Assay Development
  • TECHNOLOGY
    • Nuclear Receptor Overview
    • Assay Kit Platform & Formats
    • Nuclear Receptor Profiling & Panels
    • Environmental Testing Solutions
    • Growth Factor Receptors
    • upcyte® Hepatocytes
    • FAQ
  • RESOURCES
    • Technical Manuals
    • Safety Data Sheets
    • Scientific Whitepapers from INDIGO
    • Scientific Posters
    • New Research Publications
    • Nuclear Receptor Resource
  • CONTACT US
    • Contact INDIGO
    • Request a Quote
    • Request Information
    • Distributors
    • Terms & Conditions
      • Product Policies
      • Limited Use Disclosures
  • BLOG

Differential Activation of Nuclear Receptors by Perflunoriated Fatty Acid Analogs and Natural Fatty Acids: A Comparison of Human, Mouse, and Rat Peroxisome Proliferator-Activated Receptor Receptor-a, -b, and -c, Liver X Receptor-b, and Retinoid X Receptor-a

Print Friendly, PDF & Email

ABSTRACT

Administration of ammonium salts of perfluorooctanoate (PFOA) to rats results in peroxisome proliferation and benign liver tumors, events associated with activation of the nuclear receptor
(NR) peroxisome proliferator-activated receptor-a (PPARa). Due to its fatty acid structure, PFOA may activate other NRs, such as PPARb, PPARg, liver X receptor (LXR), or retinoid X receptor
(RXR). In this study, the activation of human, mouse, and rat PPARa, PPARb, PPARg, LXRb, and RXRa by PFOA (including its linear and branched isomers) and perfluorooctane sulfonate
(PFOS) was investigated and compared to several structural classes of natural fatty acids and appropriate positive control ligands. An NR ligand-binding domain/Gal4 DNA-binding domain chimeric reporter system was used. Human, mouse, and rat PPARa were activated by PFOA isomers and PFOS. PPARb was less sensitive to the agents tested, with only PFOA affecting the mouse receptor. PFOA and PFOS also activated human, mouse, and rat PPARg, although the maximum induction of PPARg was much less than that seen with rosiglitazone, suggesting that PFOA and PFOS are partial agonists of this receptor. Neither LXRb nor the common heterodimerization partner RXRa was activated by PFOA in any species examined. Taken together, these data show that of the NRs studied, PPARa is the most likely target of PFOA and PFOS, although PPARg is also activated to some extent. Compared to naturally occurring long-chain fatty acids, e.g. linoleic and alinolenic acids, these perfluorinated fatty acid analogs were more selective and less potent in their activation of the NRs.

To read the full article click HERE.

Date of publication: Advance Access publication 26 May  2006; Toxicological Sciences 92(2), 479-489

Author information: John P Vanden Heuvel (1); Jerry T. Thompson (1); Steven R. Frame (2); & Peter J. Gilles (2,3)

(1) Department of Veterinary and Biomedical Science and The Center for Molecular Toxicology and Carcinogenesis, The Pennsylvania State University, University Park, PA 16802
(2) DuPont Haskell Laboratory for Health and Environmental Sciences, Newark, DE 19714
(3) Department of Nutritional Sciences, The Pennsylvania State University, University Park, PA 16802

Filed Under: New Publications Tagged With: LXR, LXRβ, PPAR, PPARα, PPARβ, PPARγ, RXR

INDIGO Biosciences - The right partner for all your discovery and toxicology needs.
Search site...
Click to Insert Symbols in Search

α β γ δ Δ ε ζ κ ® ™ µ

Want More Information?

Simply fill out this form and we'll be in touch!

Resource Quick Links

  • Technical Manuals & Product Listing
  • Safety Data Sheets
  • Sample Study Report
  • Study Work Order Form

3006 Research Drive, Suite A1, State College, PA, USA 16801

+1 (814) 234-1919

  • Home
  • Products
  • Request a Quote
  • FAQ

© 2022 INDIGO Biosciences, Inc. All Rights Reserved